Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study
Year: 2019
Type: article
Abstract: The aim of this study was to evaluate the efficacy and safety of pemafibrate in people with type 2 diabetes and hypertriglyceridaemia over a 52-week period. Participants were randomly assigned to receive treatment with placebo or pemafibrate at a dose of 0.2 or 0.4 mg/d for 24 weeks (treatment period 1). The main results from treatment period 1 have been reported previously. The assigned treatment was continued up to week 52, except that the placebo was changed to pemafibrate 0.2 mg/d after week 24 (treatment period 2). The percentage changes in fasting serum triglyceride (TG) levels at week 52 (last observation carried forward) were -48.2%, -42.3%, and -46.4% in the placebo/pemafibrate 0.2 mg/d (n = 57), pemafibrate 0.2 mg/d (n = 54), and pemafibrate 0.4 mg/d (n = 55) groups, respectively. Levels of TG, non-HDL cholesterol and total cholesterol stably decreased, whereas levels of HDL cholesterol increased with pemafibrate treatments over 52 weeks. Pemafibrate was well tolerated throughout the study period. The present study is the first to show that pemafibrate treatment substantially ameliorated lipid abnormalities and was well tolerated for 52 weeks in people with type 2 diabetes and hypertriglyceridaemia.
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.13686
Institutions: Kumamoto University, Rinku General Medical Center, The University of Osaka, National Center for Geriatrics and Gerontology, Chiba University, Chiba University Hospital, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Aichi Medical University, Shiga University of Medical Science, NTT Medical Center Sapporo, Yamaguchi University, Juntendo University, Kowa (Japan), Jichi Medical University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: Elucidation of molecular pathology of aging and diseases based on multi-dimensional analysis of progeroid syndromes, Elucidation of the effects of anti-diabetes and anti-complications by activation of heat shock response pathway and translation for clinical application, Development of transvenous liver-specific mesenchymal stem cell transplantation therapy by cell-modification, Organ- and intermolecular interactions of heat stress response pathway activation that exert anti-diabetic effects
OpenAlex ID: W2918534184
